Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Dermatologic Surgery

Treating DFSP: Surgical Precision, Targeted Therapy, and Recovery

At a Glance

The primary treatment for Dermatofibrosarcoma protuberans (DFSP) is complete surgical removal with clear margins, often using Mohs surgery or wide local excision. Reconstructive surgery is frequently needed to close the wound, and targeted therapy like Imatinib can be used for specific cases.

Treating Dermatofibrosarcoma protuberans (DFSP) is a highly specialized process because of the way the tumor grows. The primary goal is R0 resection, which means the tumor is completely removed with no cancer cells left at the surgical edges (margins) [1][2]. Because DFSP has invisible, root-like “tentacles,” achieving these clear margins is the most important step in your care [3][4].

Surgical Options: Mohs vs. Wide Local Excision

There are two main ways to surgically remove DFSP. Because the tumor’s “roots” travel not only outward but also downward, both methods must remove tissue deeply—usually down to or including the fascial layer (the lining over your muscle) [5][6].

Mohs Micrographic Surgery (MMS)

Mohs surgery is increasingly considered the “gold standard” for DFSP, especially on the face, neck, or hands [7][4].

  • How it works: The surgeon removes the tumor in thin layers and examines 100% of the margins under a microscope [8][9].
  • The “Slow Mohs” Reality: Because DFSP cells can be difficult to see on standard rapid slides, surgeons often use a modified technique called “Slow Mohs.” This means the tissue is sent to a lab for permanent staining, which takes a few days [10][11]. You will likely go home with a bandaged wound and return a day or two later for either further removal or closure.
  • Benefits: This technique has the lowest recurrence rates because it maps the cancer’s roots [7][12]. It is also “tissue-sparing,” saving as much healthy skin as safely possible [7][5].

Wide Local Excision (WLE)

WLE is the traditional surgical approach and is commonly used for tumors on the trunk or limbs [5][6].

  • How it works: The surgeon removes the visible tumor plus a wide “safety margin” of healthy-looking skin—usually 2 to 3 centimeters (about an inch) in all directions outward, and deeply down to the muscle fascia [5][13].
  • Considerations: While effective, WLE removes a significantly larger volume of tissue and carries a slightly higher risk of leaving microscopic cells behind compared to Mohs [7][6].

The Reality of Reconstructive Surgery

Because DFSP surgery requires removing large or deep areas of tissue to catch the “tentacles,” the resulting surgical wound is often larger than patients anticipate. In many cases, the wound cannot simply be stitched closed. You may require reconstructive plastic surgery, such as a skin graft (moving skin from another part of your body) or a tissue flap (stretching adjacent skin over the wound) [7][4]. Often, a reconstructive surgeon will work alongside your surgical oncologist or Mohs surgeon.

Systemic Therapy: Imatinib

For some patients, surgery alone is not the best first step. Imatinib is a targeted therapy—a pill that specifically blocks the “switched-on” growth signal caused by the DFSP genetic translocation [14][15].

  • Prerequisite for Treatment: Before starting Imatinib, your tumor must undergo molecular testing (like FISH or NGS) to confirm you actually have the specific genetic mutation it targets [16][17].
  • When it’s Used: It may be used as neoadjuvant therapy (given before surgery to shrink a very large tumor) or as a long-term treatment if the cancer has spread or cannot be operated on [18][19].
  • Side Effects: Like all potent medications, Imatinib comes with side effects that can impact your quality of life. Common issues include significant fluid retention, periorbital edema (swelling around the eyes), nausea, fatigue, and muscle cramps [14][20]. You should report any of these to your medical oncologist immediately so they can be managed.

Building Your Care Team

Because DFSP is rare, it is best managed by a multidisciplinary team [1][21]. Your team should ideally include a Dermatologic Surgeon (Mohs specialist), Surgical Oncologist, Reconstructive/Plastic Surgeon, Pathologist, and potentially a Medical Oncologist [22][12].

Common questions in this guide

Should I get Mohs surgery or a wide local excision for DFSP?
Mohs surgery is often considered the gold standard, especially on the face or neck, because it examines all of the surgical margins and spares healthy tissue. Wide local excision is also highly effective and commonly used for tumors on the trunk or limbs, though it requires removing a larger area of skin.
What is Slow Mohs surgery?
Slow Mohs is a modified surgical technique used for DFSP because its cells are hard to see on standard rapid tests. The removed tissue is sent to a lab for permanent staining over a few days, meaning you will go home with a bandage and return later for the final closure.
Will I need plastic surgery after my DFSP is removed?
Because surgeons must remove deep areas of tissue to catch the tumor's invisible root-like extensions, the resulting wound is often larger than expected. Many patients require reconstructive plastic surgery, such as a skin graft or tissue flap, to properly close the area.
How does Imatinib work for DFSP?
Imatinib is a targeted therapy pill that blocks the specific growth signals caused by DFSP genetic mutations. It may be used to shrink a very large tumor before surgery, or prescribed as a long-term treatment if the cancer cannot be operated on.
Do I need genetic testing before taking Imatinib?
Yes, before you can start Imatinib, your tumor must undergo specific molecular testing. This confirms that your cancer has the exact genetic mutation that the medication is designed to target and turn off.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the location of my tumor, do you recommend Mohs surgery or wide local excision?
  2. 2.How deep will the surgery go—will it reach the fascial layer over my muscle?
  3. 3.If we proceed with wide local excision, will a reconstructive surgeon be needed to close the wound?
  4. 4.Is my tumor a candidate for neoadjuvant Imatinib to shrink it before surgery?
  5. 5.Will my tumor be genetically tested before considering Imatinib to confirm the mutation is present?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Dermatofibrosarcoma Protuberans: A Surgeon's Enigma.

    Gangadhar SM, Yadav M, Mandal NS

    Cureus 2023; (15(8)):e44144 doi:10.7759/cureus.44144.

    PMID: 37753015
  2. 2

    Wide local excision vs. Mohs Tübingen technique in the treatment of dermatofibrosarcoma protuberans: a two-centre retrospective study and literature review.

    Veronese F, Boggio P, Tiberio R, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(12)):2069-2076 doi:10.1111/jdv.14378.

    PMID: 28573714
  3. 3

    Role of diffusion-weighted magnetic resonance imaging in the evaluation of scalp dermatofibrosarcoma protuberans.

    Van Steenkiste E, Van Laethem A, Biesemans G, Pans S

    International journal of dermatology 2016; (55(2)):226-31 doi:10.1111/ijd.13050.

    PMID: 26712720
  4. 4

    Dermatofibrosarcoma Protuberans Re-excision and Recurrence Rates in the Netherlands Between 1989 and 2016.

    van Lee CB, Kan WC, Gran S, et al.

    Acta dermato-venereologica 2019; (99(12)):1160-1165 doi:10.2340/00015555-3287.

    PMID: 31410492
  5. 5

    [Dermatofibrosarcoma protuberans].

    Demouche S

    Annales de chirurgie plastique et esthetique 2025; (70(6)):470-475 doi:10.1016/j.anplas.2025.05.012.

    PMID: 41232970
  6. 6

    Wide Local Excision for Dermatofibrosarcoma Protuberans: A Single-Center Series of 90 Patients.

    Kim BJ, Kim H, Jin US, et al.

    BioMed research international 2015; (2015()):642549 doi:10.1155/2015/642549.

    PMID: 26688814
  7. 7

    Treatment of dermatofibrosarcoma of the head and neck with Mohs surgery with paraffin sections.

    González A, Etchichury D, Rivero JM, Adamo L

    Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2021; (74(5)):1061-1070 doi:10.1016/j.bjps.2020.10.062.

    PMID: 33317985
  8. 8

    Dermatofibrosarcoma Protuberans in Children.

    Sleiwah A, Wright TC, Chapman T, et al.

    Current treatment options in oncology 2022; (23(6)):843-854 doi:10.1007/s11864-022-00979-9.

    PMID: 35394606
  9. 9

    Dermatofibrosarcoma protuberans of the scalp: Surgical management in a multicentric series of 11 cases and systematic review of the literature.

    Kuhlmann C, Ehrl D, Taha S, et al.

    Surgery 2023; (173(6)):1463-1475 doi:10.1016/j.surg.2023.02.026.

    PMID: 37012145
  10. 10

    Comparing Mohs micrographic surgery and wide local excision in the management of head and neck dermatofibrosarcoma protuberans: a scoping review.

    Sanabria A, Pinillos P, Chiesa-Estomba C, et al.

    The Journal of dermatological treatment 2024; (35(1)):2295816 doi:10.1080/09546634.2023.2295816.

    PMID: 38146660
  11. 11

    Dermatofibrosarcoma protuberans: our 10-year experience on 80 patients.

    Zhou X, Sun D, Liu Y, et al.

    The Journal of dermatological treatment 2020; (31(6)):554-558 doi:10.1080/09546634.2019.1622629.

    PMID: 31116621
  12. 12

    Surgical management of dermatofibrosarcoma protuberans.

    Rust DJ, Kwinta BD, Geskin LJ, et al.

    Journal of surgical oncology 2023; (128(1)):87-96 doi:10.1002/jso.27258.

    PMID: 36999599
  13. 13

    Analysis of surgical margins and prognostic factors in dermatofibrosarcoma protuberans after wide local excision: A multicenter study of 116 Japanese patients.

    Muto Y, Fujimura T, Takahashi A, et al.

    The Journal of dermatology 2024; (51(9)):1225-1232 doi:10.1111/1346-8138.17280.

    PMID: 38775205
  14. 14

    COL1A1::PDGFB fusion-associated uterine fibrosarcoma: A case report and review of the literature.

    Rota S, Franza A, Fabbroni C, et al.

    Cancer reports (Hoboken, N.J.) 2024; (7(2)):e1969 doi:10.1002/cnr2.1969.

    PMID: 38279510
  15. 15

    Recurrent dermatofibrosarcoma protuberans treated with neoadjuvant imatinib mesylate followed by Mohs micrographic surgery.

    Fontecilla NM, Kittler NW, Geskin L, et al.

    JAAD case reports 2017; (3(6)):467-469 doi:10.1016/j.jdcr.2017.06.019.

    PMID: 28971134
  16. 16

    COL1A1-PDGFB Fusion Gene Detection Through Bulk RNA-Seq and Transcriptomic Features of Dermatofibrosarcoma Protuberans.

    Peng R, Zhang G, Li H

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2023; (49(5S)):S27-S33 doi:10.1097/DSS.0000000000003771.

    PMID: 37115997
  17. 17

    [Perianal dermatofibrosarcoma protuberans: a case report, review and update].

    Velasco Albendea FJ, Doña Girón J, Blanco Villar ML, et al.

    Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2019; (52(1)):62-68 doi:10.1016/j.patol.2018.02.004.

    PMID: 30583835
  18. 18

    Neoadjuvant imatinib as treatment preceding surgery for vulvar dermatofibrosarcoma protuberans.

    Merlo G, Cozzani E, Comandini D, et al.

    Dermatologic therapy 2021; (34(2)):e14860 doi:10.1111/dth.14860.

    PMID: 33559311
  19. 19

    Facial subcutaneous dermatofibrosarcoma protuberans treated with imatinib and monitored with magnetic resonance: A therapeutic alternative for unresectable cases.

    Navarrete-Dechent C, Shah K, Mori S, et al.

    Dermatologic therapy 2022; (35(6)):e15446 doi:10.1111/dth.15446.

    PMID: 35293090
  20. 20

    Dermatofibrosarcoma Protuberans-Like Tumor With COL1A1 Copy Number Gain in the Absence of t(17;22).

    Saab J, Rosenthal IM, Wang L, et al.

    The American Journal of dermatopathology 2017; (39(4)):304-309 doi:10.1097/DAD.0000000000000746.

    PMID: 27984233
  21. 21

    Contemporary Management of Dermatofibrosarcoma Protuberans.

    Janczewski LM, Wayne JD

    Hematology/oncology clinics of North America 2026; (40(1)):39-49 doi:10.1016/j.hoc.2025.07.004.

    PMID: 41224441
  22. 22

    Dermatofibrosarcoma protuberans (DFSP) in children: A combined multidisciplinary approach.

    Sleiwah A, Psomadakis C, Craythorne E, et al.

    Pediatric dermatology 2021; (38(1)):233-236 doi:10.1111/pde.14425.

    PMID: 33174641

This page explains DFSP treatment options for educational purposes only. Always consult your multidisciplinary healthcare team to determine the best surgical or medical approach for your specific tumor.

Get notified when new evidence is published on Dermatofibrosarcoma protuberans.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.